Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
79 hedge funds and large institutions have $84.4M invested in Navidea Biopharmaceuticals Inc. in 2015 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 27 increasing their positions, 17 reducing their positions, and 9 closing their positions.
59% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 17
6% more capital invested
Capital invested by funds: $79.4M → $84.4M (+$4.97M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 82 → 79 (-3)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
96% less call options, than puts
Call options by funds: $368K | Put options by funds: $9.93M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$1.43M |
| 2 |
PM
Platinum Management
New York
|
+$1.07M |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$646K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$490K |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
+$268K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$385K |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$155K |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$126K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$86.5K |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
-$54K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
76
Alexandria Capital
Arlington,
Virginia
| $2K | – | – | – |
|
77
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $161 | -$4.1K | -141 | -3% |
|
|
N
78
Nuveen
Charlotte,
North Carolina
| $20 | – | – | – |
|
|
79
Principal Financial Group
Des Moines,
Iowa
| – | -$54K | -1,687 | Closed |
|
|
CSS
80
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$36K | -1,129 | Closed |
|
|
SIP
81
Stoneridge Investment Partners
Radnor,
Pennsylvania
| – | -$27K | -850 | Closed |
|
82
Renaissance Technologies
New York
| – | -$25K | -775 | Closed |
|
|
RCM
83
Rotella Capital Management
Bellevue,
Washington
| – | -$20K | -642 | Closed |
|
|
PA
84
Profund Advisors
Bethesda,
Maryland
| – | -$16K | -516 | Closed |
|
|
HI
85
Hudock Inc
Williamsport,
Pennsylvania
| – | -$8K | -250 | Closed |
|
|
BFEC
86
Benjamin F. Edwards & Company
St. Louis,
Missouri
| – | -$5K | -150 | Closed |
|
87
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$3.78K | -130 | -99% |
|
|
HNB
88
Huntington National Bank
Columbus,
Ohio
| – | -$1K | -38 | Closed |
|
NAVB Hedge Fund Activity: Q2 2015 in Review
79 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q2 2015, worth a combined $84.4M — up 6.3% from $79.4M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of NAVB and 8 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 27 added.
The largest buyer was Goldman Sachs, adding an estimated $1.43M. The largest seller was BlackRock Fund Advisors, cutting an estimated $385K.
- 79 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q2 2015, down from 82 in Q1 2015.
- Funds reported $84.4M of Navidea Biopharmaceuticals Inc. stock for Q2 2015, up 6.3% quarter-over-quarter.
- 8 funds opened new Navidea Biopharmaceuticals Inc. positions in Q2 2015 and 9 closed out, a net change of -1 holder.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q2 2015 was Goldman Sachs, an estimated $1.43M added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q2 2015 was BlackRock Fund Advisors, an estimated $385K sold.
Based on aggregated 13F filings for Q2 2015.